Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-22
2005-11-22
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06967207
ABSTRACT:
The compound of the following formula:wherein R1and R2independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and suppressing effect on acid secretion, and also is highly safe. Accordingly, the substance is useful as preventive or therapeutic medicament for a gastroesophageal reflux disease.
REFERENCES:
patent: 5352685 (1994-10-01), Maruyama et al.
patent: 560348 (1993-09-01), None
CA 132:117101, Revel et al, Drugs of the Future 1999 24(9) 966-968, abstract.
B. Johansen et al., “BRL 24924, a 5-Hydroxytryptamine Type 3 Antagonist•••and Pepsin in vitro”, Digestion, 1991, vol. 48, No. 3, pp. 121-127.
Cook Rebecca
Mitsubishi Pharma Corporation
LandOfFree
Preventive or therapeutic agents for gastric or esophageal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventive or therapeutic agents for gastric or esophageal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventive or therapeutic agents for gastric or esophageal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3494026